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Abstract
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Congenital anomalies of the kidney and urinary tract (CAKUT) are a major cause of pediatric
kidney failure. We performed a genome-wide analysis of copy number variants (CNVs) in 2,824
cases and 21,498 controls. Affected individuals carried a significant burden of rare exonic (i.e.
affecting coding regions) CNVs and were enriched for known genomic disorders (GD). Kidney
anomaly (KA) cases were most enriched for exonic CNVs, encompassing GD-CNVs and novel
deletions; obstructive uropathy (OU) had a lower CNV burden and an intermediate prevalence of
GD-CNVs; vesicoureteral reflux (VUR) had the fewest GD-CNVs but was enriched for novel
exonic CNVs, particularly duplications. Six loci (1q21, 4p16.1-p16.3, 16p11.2, 16p13.11, 17q12,
and 22q11.2) accounted for 65% of patients with GD-CNVs. Deletions at 17q12, 4p16.1-p16.3,
and 22q11.2 were specific for KA; the 16p11.2 locus showed extensive pleiotropy. Using a
multidisciplinary approach, we identified TBX6 as a driver for the CAKUT subphenotypes in the
16p11.2 microdeletion syndrome.

Author Manuscript

INTRODUCTION
Congenital anomalies of the kidney and urinary tract (CAKUT) have devastating impact on
childhood renal survival1–4. A better understanding of the pathogenesis of CAKUT is
imperative to improve the prognosis of affected children5. CAKUT encompasses a broad
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spectrum of phenotypes, which can result from early disruptions in transcription factors and
signaling molecules such as PAX2, EYA1, RET, BMP45,6 and others, or are directly related
to spatiotemporal interactions of the outgrowing ureteric bud and metanephric
mesenchyme7–9. Early disruption of these interactions leads to renal agenesis, hypoplasia or
-dysplasia, whereas later perturbations in the outgrowth of the ureteric bud result in
obstructive uropathy (OU), vesicoureteric reflux (VUR) or ectopic or horseshoe kidney (EKHK)6,10–13. Maldevelopment of the lower urinary tract can result in epispadias or
hypospadias (LUTM) or posterior urethral valves (PUV)14. Genetic manipulation in mice
indicates that disruption of the same cellular pathways can lead to multiple different
genitourinary phenotypes15–19. Similarly, mutations in genes associated with Mendelian
forms of CAKUT can lead to different subphenotypes in individuals from the same
families18,20,21, suggesting that a single genetic lesion can have pleiotropic manifestations
across the spectrum of CAKUT. Conversely, differences in prevalence and severity of
structural malformations point towards distinct molecular basis and genetic architecture22,23.
To date, there are over 50 single-gene disorders underlying isolated and non-isolated (i.e.
syndromic) CAKUT5,24,25. Furthermore, a significant number of CAKUT patients carry
copy number variants (CNV) that have been previously associated with a syndrome
diagnosis or are large and extremely rare in the general population26–28. Nevertheless, a
molecular diagnosis can be established in less than 20% of affected individuals15–17,29–32,
emphasizing that large studies across the entire phenotypic spectrum of CAKUT are
indispensable to identify those genes and allelic variants that are either specific to
subcategories of disease or those that have pleiotropic effects across the entire genitourinary
tract, and to discover novel cellular pathways that are implicated in kidney and urinary
development.

Author Manuscript
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Here, we show both the presence of a distinct genetic architecture as well as pleiotropic
mutations for the different subphenotypes of CAKUT. Our CNV analysis of nearly 3,000
cases across the phenotypic spectrum of CAKUT sheds light on the genomic architecture of
disease, and implicates TBX6 as a main driver for the various CAKUT phenotypes in the
16p11.2 microdeletion syndrome.

RESULTS
Burden of rare CNVs is high in CAKUT

Author Manuscript

We conducted a study in 2,824 CAKUT cases and 21,498 population controls
(Supplementary Tables 1 and 2 and Supplementary Figure 1) to compare the prevalence of
rare CNVs that intersect genes. The case cohort represented common CAKUT
subcategories: kidney anomalies (KA; including renal agenesis, hypoplasia, dysplasia, and
multicystic dysplasia), vesicoureteral reflux (VUR), obstructive uropathy (OU; including
congenital hydronephrosis, ureteropelvic junction obstruction, ureterovesical junction
obstruction, and congenital megaureter), duplicated collecting system (DCS; including
duplications of the ureter or kidney, partial and complete), posterior urethral valves (PUV),
ectopic kidney or horseshoe kidney (EK-HK), and other lower urinary tract malformations
(LUTM; including anomalies of the bladder and anterior urethra). Our analysis focused on
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large (≥100 kb) CNVs that are present in less than 1:1,000 population controls, across
different ancestries as estimated by principal component analysis (Supplementary Figure 2).

Author Manuscript

This analysis revealed marked enrichment for large, rare CNVs in CAKUT compared to
controls (P = 1.04 × 10−24; Figure 1A), consistent across virtually all metrics examined,
including the the number of individuals with large, rare CNVs, the median size and total
CNV span per genome, and the fraction of GD-CNVs, indicating an important role for genedisrupting CNVs across the whole CAKUT spectrum (Table 1 and Supplementary Table 3).
This signal was driven by cases with and without extrarenal manifestations, since the burden
difference was still highly significant when analyzing cases without extrarenal defects
separately (P = 3.21 × 10−8; Figure 1A–B and Supplementary Figures 3 and 4). Even when
considering only simplex isolated CAKUT cases (i.e. cases without extrarenal manifestation
and with no additional CAKUT phenotypes other than the primary one), there was still an
excess burden of large, rare CNVs compared to controls (P = 1.15 × 10−8; Supplementary
Figure 5). Comparison of burden metrics for cases and controls indicated a population
attributable risk of 4.1% for large, rare CNVs ≥500 kb in CAKUT (OR 1.64, 95% CI 1.44–
1.87; P = 3.23 × 10−13). This excess burden is predominantly attributable to exonic
deletions, most prominently in the KA cases (Supplementary Tables 4 and 5). Interestingly,
we observed an enrichment for rare duplications compared to deletions in VUR and PUV
cases when compared to controls (P = 3.33 × 10−2 and P = 8.67 × 10−4, respectively;
Supplementary Figure 6). Secondary analysis also showed enrichment of the number of
genes per individual genome that were affected by rare CNVs for nearly all CAKUT
subcategories (Supplementary Table 6 and Supplementary Figure 7).
Genomic disorders inform about the genetic architecture of CAKUT

Author Manuscript

We cross-annotated all rare CNVs with a curated list of known genomic disorders
(Supplementary Table 7)33,34 and identified 45 distinct known genomic disorders (GD) in
112 (4.0%) independent cases (Supplementary Table 8, Figure 1C). Five cases carried more
than one known GD-CNV, resulting in a total number of 117 known GD-CNVs in our cohort
(Supplementary Table 9); in comparison, known GD-CNVs were found in only 134/21,498
(0.6%) population controls (OR 6.58, 95% CI 5.05–8.55; P = 7.53 × 10−41; Supplementary
Table 10).

Author Manuscript

Further annotation identified 54 large, rare, exonic CNVs in an additional 47 CAKUT cases
(1.7%) that fulfilled ACMG classification35,36 as likely pathogenic imbalances (Online
Methods and Supplementary Table 11). Among these, CNVs that can be classified as
pathogenic were an atypical deletion at the 16p11.2 locus (see below), a 300 kb deletion
involving PAX2, a 100 kb duplication containing TBX18, a 571 kb deletion spanning PBX1,
and a 6.8 Mb duplication including BMP4 (Supplementary Figure 8A–D). We also identified
overlapping duplications at the 15p11.2 locus in 5 cases with ureteric defects (VUR, OU)
and PUV, as well as two KA cases with deletions proximal to the 16p11.2 microdeletion
syndrome. In line with the burden test results, the distribution of deletions and duplications
at known and novel GD-CNV loci (Figure 1C,D) was significantly different among CAKUT
categories (6 × 2 Fisher’s Exact Test P = 8.93 × 10−5). In particular, subjects with KA and
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OU were enriched for deletion syndromes, contrary to PUV and DCS that showed an excess
of duplications at the same genomic loci.

Author Manuscript

When we examined associations with disease severity, cases who carried a known GD-CNV
were more likely to have multiple sites of the urinary tract affected (OR 1.60, 95% CI 1.05–
2.42; P = 0.02) and more frequently harbored extrarenal malformations (OR 4.79, 95% CI
3.21–7.17; P = 6.00 × 10−15) compared to cases without a known GD-CNV. However,
consistent with the burden tests conducted above, analysis of simplex isolated cases still
showed increased burden compared to controls (OR 3.12, 95% CI 2.06–4.61; P = 1.86 ×
10−7), strongly implicating the significance of GD-CNVs in milder forms of CAKUT. To
test more complex genetic models for modes of disease determination, we examined cases
and controls for second site CNVs. Among the 159 cases with GD-CNVs (112 known, 47
new/likely pathogenic: altogether called “diagnostic CNVs” (DCNVs)) eleven (6.9%)
carried more than one DCNV (Supplementary Table 12). In cases, the presence of zero, one,
or more than one DCNV increased the likelihood of extrarenal malformations (Chi-square
test for 3 × 2 table: P = 6.94 × 10−7; Supplementary Figure 9).
KA, OU, and VUR show distinct genomic characteristics

Author Manuscript
Author Manuscript

Comparison of CNV landscape between the largest CAKUT subcategories revealed both
commonalities and differences between KA, OU, and VUR (Table 2). We found significant
CNV enrichment for all three phenotypes, which was most uniformly shown by a larger
proportion of cases carrying exonic CNVs ≥100 kb compared to controls. KA cases had the
highest CNV burden (P = 9.01 × 10−25; Figure 1B), as evidenced by median CNV size and
total span as well as proportion of individuals with large imbalances that could be classified
as pathogenic GD-CNVs (80 cases with GD-CNVs, OR 12.65, 95% CI 9.40–16.94; P = 8.53
× 10−50; Table 2 and Figure 1C). After removal of individuals with a known GD-CNV, the
strength of the excess CNV burden in KA was still detectable but markedly attenuated (P =
1.27 × 10−3), consistent with the major role for GD-CNVs in the pathogenesis of KA
(Supplementary Figure 10). In contrast, VUR cases were also affected by a high CNV
burden (P = 7.56 × 10−7), but these CNVs predominantly involved duplications and were
less likely to be classified as GD-CNVs (7 cases with GD-CNVs, OR 1.71; 95% CI 0.67–
3.64; P = 0.20; Figure 1C). The large rare CNVs in VUR were mostly classified as likely
pathogenic, potentially indicating that novel syndromes account for the molecular basis of
this disorder (Table 2, Figure 1D and Supplementary Figures 3 and 10). Finally, OU cases
fell in an intermediate category, with CNVs that were not statistically larger compared to
controls, yet the excess CNV burden (P = 0.01; Supplementary Figure 3) was reflected by a
greater proportion of individuals with large imbalances that were also more likely to be
classified as pathogenic GD-CNVs (11 cases with GD-CNVs, OR 3.50, 95% CI 1.70–6.52;
P = 5.96 × 10−4; Table 3 and Supplementary Figure 3). These data suggest a distinct
genomic architecture among CAKUT subcategories, with enrichment of GD-CNVs in KA,
and enrichment for novel, large or intermediate size imbalances in VUR and OU,
respectively.

Nat Genet. Author manuscript; available in PMC 2019 July 31.
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Six GD loci account for 65% of CAKUT cases with known GD-CNVs
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We conducted a literature search, including a survey of databases of genomic variants such
as DECIPHER37,38 and ISCA35, and found either a known link to CAKUT5,23,26,39–46 or
case series or reports in which CAKUT was part of the clinical phenotype47–53 in 43 out of
45 GD-CNVs. This finding underlines that these GD-CNVs are causally related to CAKUT.

Author Manuscript

While the majority of GD-CNVs affected unique or few cases (Supplementary Table 8), six
loci explained 73 of the 112 (65%) cases who carried a known GD-CNV (Figure 2). These
common GD loci included chromosome 1q21.1 (7 cases = 6.2% of cases with a GD-CNV;
five deletions, two duplications), chromosome 4p16.1-p16.3 (Wolf-Hirschhorn syndrome; 5
cases = 4.4% of cases with a GD-CNV; all deletions), chromosome 16p11.2 (9 cases = 8.0%
of cases with a GD-CNV; eight deletions, one duplication), chromosome 16p13.11 (9 cases
= 8.0% of cases with a GD-CNV; four deletions, five duplications), chromosome 17q12 (26
cases = 23.0% of cases with a GD-CNV; 23 deletions, three duplications), and chromosome
22q11.2 (17 cases = 15.0% of cases with a GD-CNV; 14 deletions, three duplications) loci.
Genotype-phenotype correlations identified that microdeletions, but not duplications, were
enriched in upper urinary tract defects, especially KA (1q21.1, 4p16.1-p16.3, 17q12,
22q11.2), whereas the 16p11.2 microdeletion syndrome was identified in all CAKUT
subcategories, suggesting a high pleiotropic effect. These observations provide further
support that some genetic lesions result in specific CAKUT subphenotypes while other
genetic lesions, such as the 16p11.2 microdeletion syndrome, have high pleiotropic effects
across the genitourinary tract. These loci provide a list of regions that are likely to
encompass critical regulators of kidney and urinary tract development in humans, offering a
unique opportunity for gene discovery.

Author Manuscript

Exome sequencing indicates haploinsufficiency underlying CNV deletions

Author Manuscript

To test the mechanism by which pathogenic CNVs confer risk to CAKUT, we conducted
whole exome sequencing (WES) in 23 patients harboring pathogenic microdeletions at 14
independent loci (Supplementary Table 13). Based on recessive loss-of-function (LOF)
inheritance, WES would uncover a hemizygous LOF mutation on the non-deleted allele
(unmasking effect). WES was performed as previously described18,23,54. We retrieved all
identified candidate hemizygous LOF variants located within the case-specific deletion loci.
Overall we identified only one LOF variant in EFCAB12 (p.Q437*; observed once in
heterozygosity in the ExAC database55,56) in a patient affected by unilateral KA and
multiple extrarenal manifestations, including neurodevelopmental delay, epilepsy, corpus
callosum agenesis, left radial bone agenesis and a patent ductus arteriosus, who harbored a
14.9 Mb deletion at chromosome 3q13.22–13.1 (Supplementary Figure 11)57. The
EFCAB12 variant was inherited from a heterozygous unaffected mother, while the CNV
occurred de novo (Supplementary Figure 11)57. Query of 15,469 control individual exomes
at the Institute of Genomic Medicine at Columbia University did not reveal any homozygous
or compound heterozygous truncating variants, suggesting that biallelic truncating mutations
are likely not tolerated in humans and propose recessive mutations in EFCAB12 as
contributors to the developmental syndrome of this individual. In addition, we performed
clinical annotation of genes that are known to be implicated in Mendelian forms of CAKUT,
by querying WES data for an in-house gene list as described58. We did not find any
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pathogenic variants in known CAKUT genes for any of the 23 deletion carrier patients.
Hence, our WES studies suggest haploinsufficiency as main pathogenetic mechanism for the
CAKUT-associated deletion CNVs.
CAKUT is a common phenotype in the 16p11.2 microdeletion syndrome

Author Manuscript
Author Manuscript

We identified nine CAKUT cases and five controls with overlapping 16p11.2 microdeletions
(0.32% vs 0.02%; OR 13.7, 95% CI 4.1–52.2; P = 4.39 × 10−6; Figure 2, Table 3 and
Supplementary Tables 9 and 10), implicating CAKUT as an important feature of this
syndrome. To better estimate the prevalence of genitourinary malformations in individuals
who harbor this GD-CNV, we first analyzed the clinical reports from 186 cases with 16p11.2
microdeletion syndrome in the DECIPHER database (Supplementary Table 14). The most
prevalent associated conditions were abnormalities of the nervous system (92.5%),
abnormalities of head or neck (26.9%), growth defects (23.7%), and abnormalities of the
limbs (14.5%). Abnormalities of the genitourinary system (including KA, hydronephrosis,
and VUR) were reported in only 10 cases (5.4%), but these estimates likely reflect the
standard clinical indication for ordering a DNA microarray for diagnosis of a syndromic
disease, i.e. neurodevelopmental delay and dysmorphic features. In fact, abnormalities of the
skeletal system, which are a hallmark for the 16p11.2 microdeletion syndrome59,60, were
reported in only 19 cases (10.2%), since, similarly to individuals with CAKUT, these
patients are rarely referred for genetic testing. To obtain a more unbiased estimate of
prevalence of genitourinary defects in patients with 16p11.2 microdeletion, we queried the
data warehouse of the Center for Applied Genomics (CAG) at the Children Hospital of
Philadelphia (CHOP). We analyzed medical records for 42 children with the 16p11.2
microdeletion syndrome (Supplementary Table 15). Neurodevelopmental defects and brain
anomalies, and spine defects were the most prevalent conditions, recorded in 22 (52.4%) and
6 (14.2%) cases, respectively. Imaging studies and clinical data assessing the kidney and
urinary tract were available for 15 out of 42 and genitourinary anomalies were present in 6
out of these 15 cases (40.0%), highlighting that CAKUT, similar to scoliosis, is a common
feature in this syndrome characterized by incomplete penetrance. Consistent with our
observation of a high pleiotropic effect for the 16p11.2 microdeletion, the phenotype was
also variable in this cohort: two patients with OU, two with VUR, one with PUV, and one
with LUTM. These data implicate CAKUT as a significant feature of the chromosome
16p11.2 microdeletion syndrome and provide an opportunity to identify novel key regulators
of kidney and urinary tract development.
TBX6 is a driver for CAKUT in the 16p11.2 microdeletion syndrome

Author Manuscript

We recently demonstrated that the combinatorial use of genomic analyses with functional
modeling in vertebrates can lead to the identification of key drivers of CAKUT phenotypes
from microdeletion syndromes23. Analysis of breakpoints in 9 CAKUT cases with typical or
atypical 16p11.2 microdeletions identified a ~175 Kb minimal region of overlap (MRO)
predicted to harbor the genetic driver(s) for CAKUT (Supplementary Figure 12). Among the
19 genes included in the MRO, TBX6 appeared as a strong candidate: it is included in the
list of essential genes from the International Mouse Phenotyping Consortium61; it is
depleted from LOF mutations in subjects from the ExAC database (aggregate prevalence of
LOF <0.001); it has a role in paraxial and intermediate mesoderm development62,63; and its
Nat Genet. Author manuscript; available in PMC 2019 July 31.
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inactivation in humans and rodents leads to spine defects including congenital scoliosis and
spondylocostal dysostosis59,62,64–66. The connection of TBX6 mutations with vertebral
anomalies is of particular interest because of the historically well-known clinical association
between congenital scoliosis and CAKUT67–69.

Author Manuscript
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To provide a functional link between inactivation of TBX6 and CAKUT, we generated an
allelic series by cross breeding mice with two different alleles: a Tbx6 null allele
(Tbx6tm2PA)70 and a Tbx6 hypomorphic allele, the spontaneous mutant Tbx6rv (hereafter
referred to as Tbx6- and Tbx6rv, respectively) previously studied for vertebral development
and spine defects71. Since the homozygous null mutation is embryonically lethal at E9.5,
precluding analysis of the developing urinary tract, we first studied compound heterozygous
embryos (Tbx6rv/-), which retain sufficient residual expression of Tbx6 for survival past
E9.5. We studied 19 Tbx6rv/- embryos at E17.5-E18.5, and observed full penetrance of
CAKUT with variable expressivity of phenotypes characterized by unilateral or bilateral
renal agenesis, unilateral or bilateral renal hypoplasia and dysplasia, and obstructive
uropathy characterized by hydronephrosis and hydroureter (Table 4, Figure 3A–L).
Microscopic analysis of renal tissue from Tbx6rv/- embryos at stages from E13.5 to E18.5
showed variable severity of kidney anomalies (Figure 3D–L). Severe phenotypes included
unilateral or bilateral renal agenesis, rudimentary kidneys and undeveloped renal
parenchyma embedded in the paraspinal musculature (Figure 3F,I,L). Milder phenotypes
included unilateral and bilateral renal hypoplasia with hydroureter, tubule dilation and
hydronephrosis (Figure 3E,H,K). These data strongly implicate TBX6 as a major driver for
CAKUT phenotypes. Comparative analysis was performed on wildtype and Tbx6rv/embryos at E11.5 after staining with E-cadherin (Cdh1), an epithelial marker, and Pax2,
which labels mesenchymal progenitors that produce nephrons, the ureteric bud which gives
rise to the renal collecting duct system, and the common nephric duct (CND)72–74. This
analysis revealed that the events leading to CAKUT (renal parenchyma abnormalities as well
as obstruction) are present at very early stages during development (Figure 3M,N). In
wildtype E11.5 embryos, the ureteric bud has invaded the metanephric blastema and has
undergone a round of branching (Figure 3N). In the Tbx6rv/- mutant (Figure 3N), the ureteric
bud has not fully invaded the metanephric blastema and had not branched, a defect that is
predicted to lead to KA. Additional Cdh1-positive cells in Figure 3N might represent
persistent mesonephros or ectopic ureteric buds. In this latter possibility, ectopic buds would
explain the duplication of kidney and ureter phenotype as observed in Figure 4.
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Since more subtle CAKUT phenotypes like OU or DCS may require a minimum glomerular
filtration rate or might be masked in more severe models, we examined a milder model that
might be closer to the genetic architecture of humans harboring the 16p11.2 microdeletion
syndrome. We therefore analyzed embryos homozygous for the Tbx6 hypomorphic allele
(Tbx6rv/rv). We generated 25 homozygous Tbx6rv/rv animals at E15.5 (n=10), E18.5 (n=10),
and P0 (n=5) and observed incomplete penetrance and variable expressivity of multiple
phenotypes that are typical of human CAKUT, including mild unilateral or bilateral
hypoplasia with asymmetric kidneys, bifid ureter or DCS, and OU with profound
hydronephrosis (Table 4 and Figure 4). This pleiotropy of CAKUT phenotypes, ranging
from renal parenchyma defects (KA) to hydronephrosis (OU), duplication of ureters (DCS)
is highly reminiscent of the pleiotropic manifestations of the 16p11.2 microdeletion in
Nat Genet. Author manuscript; available in PMC 2019 July 31.
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humans, suggesting that TBX6 gene dosage is a major determinant for the pathogenesis of
CAKUT and the observed variable expressivity of phenotypes in this syndrome.

DISCUSSION

Author Manuscript

CAKUT has profound impact on child health and alone accounts for about 50% of kidney
failure requiring dialysis and transplantation in children1,3,75–78. Moreover, CAKUT is often
accompanied by extrarenal comorbidities, such as neurodevelopmental and cardiovascular
diseases, contributing further to the disease burden in affected children5,26,27,79.
Understanding the genetic architecture of CAKUT has important implications for the
development of therapeutic tools that aim to slow down progression of kidney disease and to
mitigate the associated neurocognitive and cardiac disease. In that respect, besides the value
in achieving molecular diagnosis and hence solving the etiology of disease. In this respect,
it, is relevant to address two features of CAKUT: incomplete penetrance and variable
expressivity of disease. While prediction of a targeted treatment that prevents or reverses the
disease is still limited by current knowledge, understanding the intrinsic inter-individual
mechanisms of compensation or amplification of disease are of critical for devising
treatments that might slow down or halt progression of kidney disease and associated
extrarenal malformations.

Author Manuscript
Author Manuscript

The study of CNVs has provided enormous insight into the genetic architecture of many
developmental traits80–8889. We conducted a large study on rare CNVs in nearly 3,000
CAKUT cases and over 21,000 controls. By studying the burden of rare CNVs, we identified
that KA, OU, and VUR are particularly enriched for large and rare structural variants that
affect coding regions of the genome. When examining known GD-CNVs, we found
particular enrichment in CAKUT cases with KA, OU, DCS, and PUV when compared to
controls. Overall, we identified 45 distinct GDs at 37 independent genomic loci in 4.1% of
the CAKUT cases, indicating substantial genetic heterogeneity. We identified novel GDCNVs in an additional ~2% of CAKUT cases, providing multiple novel susceptibility loci to
kidney disease. With respect to mechanism, WES in cases harboring deletions was
consistent with haploinsufficiency as the most frequent pathogenic mechanism in individuals
affected by GD-associated deletions. Moreover, increased burden of second site CNVs was
associated with KA and increased prevalence of extrarenal malformations. These data
indicate a role for background genomic burden in variable penetrance and expressivity of
disease. CNVs at six of the known 37 loci accounted for ~65% of the cases with a known
GD, thus identifying major susceptibility CNVs for CAKUT. At these six loci, deletions
were associated with KA, whereas duplications were enriched in cases with ureteric and
lower tract defects, such as DCS and PUV. This preliminary observation gives rise to the
hypothesis that CAKUT subcategories such as ureteric and lower urinary tract defects (DCS,
PUV) may represent, at a molecular level, mirror traits of conditions affecting the upper
urinary tract (KA, OU). This “mirroring phenomenon” has been recognized in autism
spectrum disorder caused by structural variation at the 16p11.2 in which patients with
deletions show macrocephaly and patients with duplications are microcephalic90,91. Larger
human cohorts and experimental data will be required to investigate this hypothesis. A closer
look at common GD loci assigns specificity to CAKUT subcategories, such as deletions, but
not duplications, at 4p (Wolf-Hirschhorn syndrome)92, 17q12 (renal cysts and diabetes
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syndrome)40, and 22q11.2 (DiGeorge syndrome)93, that were nearly exclusively identified in
cases with upper urinary tract malformations (mainly KA). On the other end, microdeletions
at 16p11.2 were observed across the whole phenotypic spectrum of CAKUT, underlining the
highly pleiotropic effect of this genomic region on human kidney and urinary tract
development. The finding that pleiotropic urogenital defects are an important feature of this
syndrome was replicated in two independent series from DECIPHER and CHOP.

Author Manuscript

We previously reported on the potential of large-scale genetic studies coupled with
functional modeling in vertebrates in the identification of genetic drivers for kidney
phenotypes of microdeletion syndromes23. Here we focused on the 16p11.2 microdeletion
syndrome, because its pleiotropic effect and incomplete penetrance provide an ideal scenario
to identify genetic factors that might be amenable for devising therapeutic intervention.
Deletion mapping and prioritization analyses pointed to TBX6 as the main genetic driver for
CAKUT in cases with this syndrome. Tbx6 mouse allelic series showed that compound
heterozygous embryos for a null (Tbx6tm2Pa) and a hypomorphic (Tbx6rv) allele displayed
fully penetrant CAKUT with variable expressivity of phenotypes, from bilateral renal
agenesis to hypodysplasia and obstructive uropathy. Analysis of E11.5 embryonic tissue
stained for renal progenitors and epithelial markers suggested that the initiating events for
the CAKUT phenotypes are likely to occur very early in development in these mice. These
data are in line with recent fate mapping studies that show that Tbx6 is expressed in renal
progenitor cells prior to commitment to ureteric bud or metanephric mesenchyme lineages94.
When we analyzed embryos and mice with milder Tbx6 inactivation (Tbx6rv/rv) as a closer
model to the human 16p11.2 microdeletion, we observed incomplete penetrance of multiple
kidney and urinary tract malformations. Interestingly, similar to our 16p11.2 microdeletion
cases, mutant mice showed phenotypes across the phenotypic spectrum of CAKUT,
including KA, OU and DCS. Overall, our mouse data at least partly intimate that the
variable expressivity and incomplete penetrance of CAKUT in cases with the 16p11.2
microdeletion is attributable to a fine regulation of TBX6 gene expression during
organogenesis.
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In summary, with this study on children and young adults with kidney and urinary tract
malformations we provide significant insight into the genomic landscape of human CAKUT.
We identify several susceptibility genetic loci and genes, and we highlight TBX6 as a main
genetic driver for CAKUT in cases with the chromosome 16p11.2 microdeletion syndrome,
with significant implications for understanding, and potentially modifying, penetrance of
disease.

Author Manuscript

URLs
Annovar: http://annovar.openbioinformatics.org/en/latest/
ATAV: https://redmine.igm.cumc.columbia.edu/projects/atav/wiki
DECIPHER: https://decipher.sanger.ac.uk/
Exome aggregation consortium: https://exac.broadinstitute.org
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ISCA: https://www.iscaconsortium.org/
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Python Software Foundation: https://www.python.org/
•

lifelines: https://github.com/CamDavidsonPilon/lifelines/

•

pandas: https://pandas.pydata.org/

R Foundation for Statistical Computing: https://www.R-project.org/
•

dplyr package: https://CRAN.R-project.org/package=dplyr

•

survival package: https://CRAN.R-project.org/package=survival

Seattle seq: http://snp.gs.washington.edu/SeattleSeqAnnotation138/
UCSC genome browser: https://genome.ucsc.edu

Author Manuscript

METHODS
Study cohorts and Methods, including statements of data availability and any associated
accession codes and references, are available in the online version of the paper.

ONLINE METHODS
Study subjects

Author Manuscript

CAKUT cases consisted 2,824 affected, unrelated individuals with different subphenotypes
across the entire CAKUT spectrum. Cases were recruited in the United States, Europe and
Brazil (for an overview of recruitment sites, see Supplementary Figure 1). Baseline
characteristics of the study cohort are shown in Supplementary Table 1. One in every four
cases presented with more than one CAKUT phenotype (i.e. complex CAKUT), whereas a
significant proportion of patients had extrarenal manifestations such as neurocognitive
defects, congenital heart disease or dysmorphic features. A positive family history for renal
disease was identified in 15% of the cases. Cases included CAKUT patients from the
CKiD27 and KIMONO28 studies; genotyping results of 823 (29%) subjects had been
partially reported in previous publications23,26–28. The control population consisted of
21,498 individuals recruited as part of genome-wide genotyping studies of complex traits
that are not associated to nephropathy or developmental defects (Supplementary Table 2).
CNV discovery and annotation

Author Manuscript

Genomic DNA was obtained from peripheral blood samples or, in the case of CKiD
participants, lymphoblastoid cell lines derived from peripheral blood samples. Genome-wide
genotyping was performed in all cases and controls using HumanHap550 or higher density
Illumina (San Diego, CA, USA) or Affymetrix SNP6.0 (Santa Clara, CA, USA) microarrays
(Supplementary Table 2). Raw data processing and subsequent analyses were performed in
the same fashion for both cases and controls to avoid bias.
Raw data was first processed with Affymetrix Power Tools and the PennCNV-Affy protocol
or with Illumina GenomeStudio v2011, to obtain probe level logR-ratio and b allele
frequency values. Raw intensity data were processed in GenomeStudio v2011 (Illumina).
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PennCNV software95 was used to determine CNV calls. PennCNV and PLINK software96
were used for quality control. Principal component analysis (PCA) was conducted using
smartPCA97 based on SNP genotypes derived from the same genotyping arrays. CNV
calling and all analyses were performed on hg18 coordinates, CNVs were then mapped to
hg19 using UCSC liftover software (see URLs). Only high quality CNVs with confidence
scores ≥30 were included in the analyses based on independent experimental validation from
our prior CNV study on kidney anomalies (KA)26.

Author Manuscript

CNVs in cases were compared to those in controls and to known CNV coordinates, and
annotated with RefGene (see URLs) and curated sets of genes using custom Perl code98.
Known CNVs were based on the DECIPHER37,38 and the International Standards for
Cytogenomic Arrays (ISCA) databases35 and the literature (Supplementary Table 7).
Curated sets of genes included those known to be associated with kidney disease and/or
development from the OMIM and MGI databases and the literature. Two CNVs were
considered to be identical when they had the same copy number value and had a reciprocal
overlap equal to or greater than 70%. All reported CNVs were visually inspected using
Illumina Genome Viewer 1.9.0 or Affymetrix ChAS to exclude potential artifacts.
CNV classification

Author Manuscript

CNVs were classified as known genomic disorders (GD-CNV) or likely pathogenic CNVs
(“novel GD-CNV”). A CNV was defined as a known GD-CNV when it overlapped at least
70% of a known syndromic CNV. The criteria to define a likely pathogenic CNV were
adapted from prior recommendations for interpretation of microarray data26–28,35. A CNV
was classified as likely pathogenic if it (1) intersected at least one exon, (2) was at least 100
kb in size, (3) had a frequency in controls of at most 0.02%, (4) did not overlap (<70%) with
a benign or likely benign CNV in the ISCA database and fulfilled at least one of the
following additional criteria: (a) ≥70% overlap with a reported pathogenic or likely
pathogenic CNV in the ISCA database, (b) intersected a causative autosomal dominant gene
for CAKUT in humans or mice and/or (c) is the reciprocal of a known GD-CNV
(coordinates with ≥70% overlap). Known GD-CNV and likely pathogenic taken together
were termed as ‘diagnostic CNVs’. CNVs that did not meet the criteria for diagnostic CNVs
were defined as variants of unknown significance, if they were at least 100 kb in size and
had a frequency of at most 0.1% in controls, including homo-/hemizygous deletions of loci
that underlie a recessive disorder for human disease with a renal phenotype.
CNV burden analysis

Author Manuscript

We restricted burden analyses to autosomal CNV of size ≥100 kb in cases and controls, with
a frequency ≤1% in the whole control dataset and in any one control cohort comprising it.
CNVs were further filtered at a frequency ≤0.1% in control population subgroups based on
PCA, to avoid including CNVs that might be relatively common within ancestry groups
represented in controls. Prior to determining the CNV burden, seven cases (5 KA, 1
vesicoureteral reflux and 1 lower urinary tract malformations) and 8 controls were removed
because they were unmatched outliers in PCA, yielding a dataset of 2,817 cases and 21,490
controls for burden analyses.
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Whole exome sequencing was performed on 23 CAKUT patients harboring 14 distinct
known or novel GD-CNVs at the New York Genome Center (NYGC). Briefly, for each
capture experiment, 1 μg of genomic DNA was fragmented, linkers were ligated to the ends
and a library was prepared. Next, genomic DNA was annealed to Agilent V4 capture probes,
and bound genomic DNA was eluted and subjected to Next-Generation sequencing
performed on an Illumina HiSeq 2500 machine. Sequence reads were converted to FASTQ
format and mapped to the reference genome. We used uniform procedures for variant calling
to prevent technical bias. Samples were processed using a consistent alignment and variant
calling pipeline, consisting of primary alignment using bwa-0.5.10, duplicate removal using
Picard tools, index realignment and variant calling using GATK 3.6, and variant annotation
using snpEff-3.3, AnnoVar (see URLs), and SeattleSeq (see URLs), with EnsemblGRCh37.73 annotations.

Author Manuscript
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After variant calling, resultant calls and their underlying quality statistics were then stored in
a database of variants (AnnoDB) that is used by Analysis Tool for Annotated Variants
(ATAV) analyses (see URLs). Next, we queried ATAV for the individual deleted regions of
all 23 CAKUT cases and annotated all hemizygous variants (minimal coverage >8X,
minimal genotype quality score >30) with a minor allele frequency of <1% (autosomal
recessive model) in the Exome Aggregation Consortium database (ExAC) and in 3,653
ethnically-matched controls available in-house controls, and with a Combined Annotation
Dependent Depletion (CADD) score ≥20 (i.e. strongly predicted to be deleterious). We
retained one homozygous variant in one individual CAKUT case: a homozygous truncating
mutation in EFCAB12 found in a case with a 14.9 Mb deletion at chromosome 3q13.22–13.
The variant was confirmed by Sanger sequencing according to standard protocols. Finally,
we queried the ExAC database as well as the data warehouse of the Columbia Institute of
Genomic Medicine (IGM), which contains whole exome data for 15,469 control individuals
that are recruited for other reasons than chronic kidney disease. We did not find any
homozygous or compound heterozygous truncating variants in EFCAB12. We performed
clinical annotation of genes that are known to be implicated in Mendelian forms of CAKUT,
by querying WES data for an in-house gene list as previously described58. We did not find
any pathogenic variants in known CAKUT genes for all deletion carrier patients
Generation and analysis of Tbx6 mutant mice and embryos

Author Manuscript

The null allele null expression reporter allele, Tbx6tm2Pa, which deletes exon 2, part of exon
3 and has an H2B-EYFP fusion gene inserted in frame into exon 170, was maintained on a
mixed genetic background of 129 and ICR (Taconic). B6L-Tbx6rv/J mice (JAX) were mated
with C57BL/6Tac mice (Taconic) and maintained in a small closed colony. Embryos were
collected from timed matings of mice heterozygous for either allele, with noon on the day of
the plug considered embryonic day (E) 0.5. Embryos were genotyped by PCR using the
following primers pairs for Tbx6tm2Pa (1) 5’-GTACCATCCACGAGAGTTGTAC-3’, (2) 5’GGGAAGAATGAGGATCCAGG-3’ to obtain a 220bp wild type allele fragment; and (3)
5’-ATTGCACGCAGGTTCTCCGG-3’; (4) 5’-GTCACGACGAGATCCTCGCC-3’ to obtain
a 550bp mutant allele fragment. For Tbx6rv (1) 5’-CTCGCAGCTTCACTAGTCC-3’, (2) 5’-
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GTGTCTGGCGTATCAGCTCA-3’ to obtain a 322bp wild type allele fragment and 504bp
mutant allele fragment.

Author Manuscript

We analyzed different allele combinations for the Tbx6 null (Tbx6tm2Pa) and hypomorphic
(Tbx6rv) alleles. Hematoxylin and eosin (H&E) staining: embryos were fixed overnight in
4% PFA and dehydrated through a graded ethanol series (25–50-75–100%) followed by
Xylene washes. The embryos were incubated in 2 changes of paraffin wax at 55°C under
vacuum. The embryos were then embedded in paraffin wax and sectioned at 10μm. Sections
were dewaxed in Xylene, rehydrated through ethanol, stained with Harris haematoxylin and
Eosin-Y, and finally dehydrated before mounting in Cytoseal. Immunostaining: embryos
were fixed in 4% PFA. Tissues were dehydrated into 100% methanol post-fixation. For
sectioning, tissues were embedded in paraffin or frozen in OCT and sectioned at various
thicknesses (5–20μm). Paraffin sections were deparaffinised with Histoclear and rehydrated
via an ethanol-series. Cryosections were prepared for immunolabelling by removing OCT
by washing in PBS. Antibodies: Cdh1: Goat R&D AF741 at 1:400 dilution. Pax2: Rabbit
Zymed 716000 1:70.
Statistical analysis

Author Manuscript

All burden metrics calculations, statistical tests and plots were performed with R v3.1
software (R Core Team 2016. R: A language and environment for statistical computing. R
Foundation for Statistical Computing, Vienna, Austria, see URLs) and its dplyr (Hadley
Wickham and Romain Francois (2016). dplyr: A Grammar of Data Manipulation, see
URLs), survival (Therneau T (2015). A Package for Survival Analysis in S. version 2.38,
and ggplot299 packages, and the Python v2.7 language (see URLs) and its package
pandas100 and lifelines (see URLs). Unadjusted P-values were reported for all tests.
Summary statistics (mean, standard deviation, median, interquartile range) were calculated
for CNV metrics such as size and total span, and non-parametric Wilcoxon test was used for
comparison between cases and controls. Proportions were compared using 2-sided Fisher’s
Exact test. Kaplan-Meier survival curves were calculated to represent the largest CNV per
genome and non-parametric log-rank test was used to compare the survival distributions
between cases and controls. Logistic regression was used to test if the number of genes
intersected by large and rare CNVs detected (quantitative predictor) was associated with the
case-control status (outcome). The reciprocal cumulative distribution of the number of
intersected genes in cases versus controls were plotted.
Data Availability Statement

Author Manuscript

Raw data that support the findings of these study will in part be available from the
corresponding authors upon reasonable request and in part available from dbGaP (https://
www.ncbi.nlm.nih.gov/gap; accession pending). Some restrictions may apply according to
participants’ consent and privacy protection. All images generated from mouse experiments
reported in this study will also be available from the corresponding authors upon reasonable
request.
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Code Availability Statement
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Custom Perl code used for CNV comparison and annotation as well as R and Python code
used in burden analyses are available upon request from the corresponding authors.
Ethical Statement
All aspects of the study involving human research participants adhered to the principles of
the Declaration of Helsinki and the study protocol was approved by the Institutional Review
Boards (IRB) of Columbia University Medical Center and each participating recruitment
site. Signed written informed consent by the participant and/or their parents or guardians
was obtained according to the protocol of local IRBs.
All animal experiments followed protocols approved by the Institutional Animal Care and
Use Committee at Columbia University.
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Refer to Web version on PubMed Central for supplementary material.
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FIGURE 1.

Burden of rare copy number variations in CAKUT cases compared to controls. A, B. Burden
of large, rare, exonic CNVs in all CAKUT cases and controls (A) and in KA and VUR cases
and controls (B). C, D. Prevalence of known genomic disorders (C) and novel likely
pathogenic copy number variants (D) in CAKUT cases and controls. Deletions are marked
in red, duplications are marked in green. KA, OU, PUV and DCS were significantly
enriched for genomic disorders. The genomic architecture of KA cases was predominantly
devised by deletions, while the genetic basis of PUV and DCS cases mostly constituted of
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duplications. CAKUT = congenital anomalies of the kidney and urinary tract, DCS = duplex
collecting system, EK-HK = ectopic kidney/horseshoe kidney, ERM = extrarenal
malformations, KA = kidney anomaly, Mb = megabases, OU = obstructive uropathy, PUV =
posterior urethral valves, VUR = vesicoureteral reflux.
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FIGURE 2.

Common genomic disorders loci in CAKUT cases and their prevalence in controls.
Deletions are marked in red, duplications are marked in green. Among these common
genomic loci, the chromosome 16p11.2 locus showed high pleiotropy, whereas the WolfHirschhorn, 17q12 and 22q11.2 loci were mostly identified in KA cases. CAKUT =
congenital anomalies of the kidney and urinary tract, Ctrls = controls, DCS = duplex
collecting system, EK-HK = ectopic kidney/horseshoe kidney, KA = kidney anomaly,
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LUTM = other lower urinary tract malformation, OU = obstructive uropathy, PUV =
posterior urethral valves, RCAD = renal cysts and diabetes, VUR = vesicoureteral reflux.
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FIGURE 3.

Analysis of urinary tract phenotypes in Tbx6rv/- mutants. A-C. Whole mounts of urogenital
tracts isolated from E18.5 wild type (A) and Tbx6rv/- mutants showing severe bilateral renal
hypoplasia (B) and unilateral renal agenesis with contralateral renal hypoplasia (C); K =
kidney, U = ureter, B = bladder. D-F. H&E stained sagittal sections from E18.5 wild type
(D) and Tbx6rv/- mutants (E,F). In the wild type it is appreciable the normal developing
nephrogenic zone (nz) and kidney medulla (m). The arrows in E point to the dilated renal
pelvis (upper arrow) and ureter (lower arrow), which are indicative of hydronephrosis and
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hydroureter, respectively. In E the kidney parenchyma also appears severely hypoplastic.
The arrowhead in F points to the rudimentary kidney, which is embedded in paraspinal
musculature. Few dilated tubule and microcysts are present. G-I. H&E stained kidney from
and E15.5 wild type embryo (G) and E15.5 Tbx6rv/- mutant embryos (H, I). The mutants
show moderate to severe hypoplasia with reduction of nephrogenic zone (nz) (H); the
arrowhead indicated severely underdeveloped kidney tissue with tubule dilation and
microcysts (I). J-L. H&E histological analysis of kidneys from E13.5 wild type embryos (J)
and Tbx6rv/- mutants (K,L). The arrowheads point to the rudimentary kidneys that are
embedded in the body wall. M,N. Immunostaining of E11.5 wild type and Tbx6rv/- mutant
embryos stained with Pax2 (red) and Cdh1 (green) showing the ureteric bud (ub) nephron
progenitors (np), and nephric duct (nd). Note in the wild type embryo, the ureteric bud has
invaded the metanephric mesenchyme and branched, while in the mutant, the ureteric bud
has not fully invaded the metanephric mesenchyme.
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FIGURE 4.
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Analysis of urinary tract phenotypes in Tbx6rv/rv mutants. A-C. H&E stained sagittal
sections from a wild type P0 pup (A) and P0 Tbx6rv/rv pups (B,C). In the wild type can be
appreciated the renal cortex (rc) resulting from the development of the nephrogenic zone; the
medulla (m) and the renal pelvis (p). The arrows in B point to the duplicated kidneys. The
arrows in C point to hypoplastic kidney and the dilated renal pelvis and proximal ureter. DF. H&E stained sections from E15.5 wild type embryo (D) and Tbx6rv/rv mutant embryos
(E,F). The arrow in E points to the dilated renal pelvis and proximal ureter. The arrows in F
points to the hypoplastic kidney and dilated ureter.
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copy number variation, DCS = duplication of the collecting system and/or ureter, EK-HK = ectopic kidney-horseshoe kidney, KA = kidney anomaly, kb = kilobases, LUTM = other lower urinary tract
malformation, OR = odds ratio, OU = obstructive uropathy, PUV = posterior urethral valves, VUR = vesicoureteral reflux.

4.41 ×

3.30 (2.54–4.22)

2.20 (1.81–2.67)

P Fisher’s exact

10−17

79 (7.3)

141 (5.0)

≥1,000 kb: n (%)

10−14

5.67 × 10−15

3.23 × 10−13

P Fisher’s exact

OR (CI)

2.20 (1.79–2.58)

154 (14.2)

3.13 ×

1.64 (1.44–1.87)

316 (11.2)

≥500 kb: n (%)

OR (CI)

1.35 ×

10−10

1.62 (1.40–1.87)

1.43 (1.30–1.58)

P Fisher’s exact

10−12

260 (24.0)

615 (21.8)

≥250 kb: n (%)

OR (CI)

1.02 × 10−17

4.01 × 10−9

P Fisher’s exact

426 (39.4)

1,083

1.41 (1.24–1.60)

1,044 (37.1)

2,817

KA

1.28 (1.18–1.39)

OR (CI)

≥100 kb: n (%)

Total n

All CAKUT

VUR

Author Manuscript

Distribution of largest, rare, exonic CNV per individual across different size thresholds
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TABLE 2.

Author Manuscript

Comparison of CNV landscape across major CAKUT subcategories
CAKUT
(n=2,824)

KA
(n=1,088)

OU
(n=512)

VUR
(n=660)

Controls
(n=21,498)

Median CNV size (kb) (IQR)

245 (315)

258 (394)

223 (244)

248 (273)

223 (248)

P value

3.4 × 10−6

3.6 × 10−6

0.87

1.9 × 10−2

-

‡
Median total CNV span (kb) per genome (IQR)

350 (598)

414 (815)

306 (451)

353 (503)

300 (437)

P value

1.4 × 10−7

1.9 × 10−8

0.61

1.7 × 10−2

-

37.1

39.3

38.9

37.2

31.5

4.0 × 10−9

1.0 × 10−7

5.3 × 10−4

2.2 × 10−3

-

10.5

12.6

10.4

9.7

8.1

1.6 × 10−5

1.0 × 10−6

7.1 × 10−2

0.12

-

4.1

7.4

2.1

1.1

0.6

0.20

-

‡

% individuals with at least 1 large, rare CNVs

‡

P value
% individuals with at least 2 large, rare CNVs

‡

Author Manuscript

P value
% individuals with known GDs
P value

7.5 ×

10−41

8.5 ×

10−50

6.0 ×

10−4

‡
Ratio of No. of large, rare deletions: duplications

0.90

1.02

1.05

0.74

0.94

P value

0.34

0.35

0.37

3.3 × 10−2

-

CNVs refer to exonic CNVs ≥100 kb with frequency of < 1:1,000 in controls.

‡

Metrics derived from burden analysis.

CAKUT = congenital anomalies of the kidney and urinary tract, CNV = copy number variation, GD = genomic disorder, IQR = interquartile range,
KA = kidney anomaly, OU = obstructive uropathy, VUR = vesicoureteral reflux.
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Author Manuscript
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M

M

F

M

F

M

M

M

M

CAKUT1

CAKUT2

CAKUT3

CAKUT4

CAKUT5

CAKUT6

CAKUT7

CAKUT8

CAKUT9

White

White

Admixed

White

White

White

White

Black

White

Ethnicity

16

16

16

16

16

16

16

16

16

Chr

29.9

29.6

29.6

29.5

29.5

29.5

29.5

29.5

28.4

32.6

30.1

30.1

30.1

30.1

30.1

30.1

30.1

30.1

End
(Mb)

2.7

0.5

0.5

0.6

0.6

0.6

0.6

0.6

1.7

Size
(Mb)

94

34

28

40

30

31

31

31

69

Number of
genes

N

NA

NA

NA

NA

0

NA

NA

9

Age of
Diagnosis
(years)

KA

KA

DCS

KA

VUR

PUV

KA

OU

KA

Phenotype

N

N

Y

N

N

Y (VUR, KA
bilateral)

N

N

N

Additional
CAKUT

Y (craniofacial dysmorphias,
abnormality of the feet, cardiac
defect, corpus callosum hypoplasia)

Y (cryptorchidism)

N

Y (craniofacial dysmorphia, radial
agenesis, bilateral thumb aplasia)

Y (scoliosis)

N

N

N

N

Extrarenal
malformations

NA

NA

NA

N

NA

Y

NA

NA

NA

Family
history

5

NA

NA

44

NA

158

NA

NA

NA

eGFR
(ml/min/1.73m2)

CAKUT = congenital anomalies of the kidney and urinary tract, Chr = chromosome, DCS = duplicated collecting system and/or ureter, eGFR = estimated glomerular filtration rate, F = female, KA = kidney
anomaly, M = male. Mb = megabases, N = no, NA = not available, OU = obstructive uropathy, PUV = posterior urethral valves, VUR = vesicoureteral reflux; Y = yes.

Sex

Case

Start
(Mb)

Clinical characteristics of CAKUT cases affected by the heterozygous 16p11.2 microdeletion.
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TABLE 4.
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Tbx6 dosage-dependent kidney and urinary tract phenotypes
Tbx6rv/Phenotype

Tbx6rv/rv

Tbx6+/−

Tbx6rv/+

Tbx6+/+

E17.5–E18.5*

E15.5

E18.5

P0-P1

E18.5*

E18.5*

E18.5

Bilateral renal agenesis

4/19

0/8

0/5

0/3

0/4

0/6

0/12

Unilateral renal agenesis

6/19

0/8

0/5

0/3

0/4

0/6

0/12

Bilateral renal hypoplasia/dysplasia

8/19

3/8

0/5

0/3

0/4

0/6

0/12

Unilateral renal hypoplasia/dysplasia

3/19

3/8

4/5

1/3

0/4

0/6

0/12

Hydronephrosis/ hydroureter

5/19

1/8

1/5

3/3

0/4

0/6

0/12

Duplex kidney/ureter

1/19

0/8

4/5

0/3

0/4

0/6

0/12

19/19 (100)

6/8 (75)

4/5 (80)

3/3 (100)

0/4 (0)

0/6 (0)

0/12 (0)

Total embryos with defects (%)

*

Author Manuscript

Based on gross morphology only. We analyzed four Tbx6+/− and six Tbx6+/rv E18.5 embryos by gross morphology thus hampering ability to
assess milder phenotypes and incomplete penetrance in these embryos.
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